Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2025 17:00 ET | Source: PainReform Ltd

PainReform Provides Year-End Business Update

TEL AVIV, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a specialty pharmaceutical company focused on the reformulation of established...
March 05, 2025 11:00 ET | Source: PainReform Ltd

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

TEL AVIV, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
February 18, 2025 08:30 ET | Source: PainReform Ltd

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

DeepSolar brings new customer base in creation, including major utility-scalesolar operators and independent power producers, whilebreaking into the residential solar market The Company remains...
December 27, 2024 08:30 ET | Source: PainReform Ltd

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
November 20, 2024 08:30 ET | Source: PainReform Ltd

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
November 07, 2024 17:00 ET | Source: PainReform Ltd

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

This notification has no immediate effect on the listing or trading of PainReform’s ordinary shares on the Nasdaq Capital Market TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd....
September 11, 2024 08:30 ET | Source: PainReform Ltd

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
September 10, 2024 09:46 ET | Source: PainReform Ltd

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
August 21, 2024 08:30 ET | Source: PainReform Ltd

PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures

PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110’s Competitive Edge Over Leading Pain Management Products TEL AVIV, Israel, Aug. 21, 2024 ...
August 20, 2024 08:30 ET | Source: PainReform Ltd

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...